At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 226 enrolled
Drug / intervention
124-Iodine-cG250 (124I-cG250) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250)
In Brief
A Phase 3 clinical trial evaluating 124-Iodine-cG250 (124I-cG250) and CT for Renal Cell Carcinoma and Kidney Cancer. Completed, enrolled 226 participants across 14 sites.
Detailed Summary
This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma, Kidney Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2008
Enrollment StartMar 2008
Primary CompletionNov 2009
Study CompletionDec 2009
TodayJul 2026
First PostedFeb 4, 2008
Enrollment StartMar 1, 2008
Primary CompletionNov 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.4 years ago
Interventions
124-Iodine-cG250 (124I-cG250)drug
i.v. and PET/CT scan 4+/-2 days after administration
CTprocedure
contrast enhanced CT scan